Evidence map›Paper›PMID 27894752›Full record

ArticleGynecologic oncology2017

Trends in cervical cancer incidence in younger US women from 2000 to 2013.

Daniel C Beachler, Joseph E Tota, Michelle I Silver, Aimée R Kreimer, Allan Hildesheim, Nicolas Wentzensen, Mark Schiffman, Meredith S Shiels

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Gynecologic oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Daniel C BeachlerDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA. Electronic address: daniel.beachler@nih.gov.
Joseph E TotaDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Michelle I SilverDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Aimée R KreimerDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Allan HildesheimDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Nicolas WentzensenDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Mark SchiffmanDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Meredith S ShielsDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
National Cancer Institute · US

Funding

HPV Vaccine TrialZIACP010217 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI KREIMER, AIMEE · 2011 to 2025
$42.3M
HPV and cancer at multiple anatomic sitesZIACP010209 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI KREIMER, AIMEE · 2010 to 2025
$7.9M
Intramural NIH HHS Z99 CA999999Intramural NIH HHS ZIA CP010209
6 · The paper itself

Abstract

objectiveThis study aimed to assess the temporal trends in invasive cervical cancer (ICC) incidence rates among 21-25year-olds. US guidelines no longer recommend screening prior to age 21, and concerns have been raised that delayed screening initiation may increase ICC incidence among young women.

methodsThis study utilized ICC incidence data from 18 US population-based cancer registries in SEER from 2000 to 2013 and Pap test prevalence data from the Behavioral Risk Factor Surveillance System from 1996 to 2012. Trends were evaluated with annual percent changes (APCs) using Joinpoint regression.

resultsThe prevalence of never having a Pap test before age 21 increased from 22.0% in 1996-2004 to 38.3% in 2006-2012 (APC=+5.48, 95%CI=+4.20, +7.50). Despite this decline in screening, ICC incidence among 21-23year olds significantly declined between 2000 and 13 (APC=-5.36, 95%CI=-7.83,-2.82), particularly from 2006 to 2013 (APC=-9.70, 95%CI=-15.79, -3.17). ICC incidence remained constant among 24-25year olds (APC=+0.45, 95%CI=-2.00, 2.97). Compared to women born in 1978-1985, women born in 1986-1991 had a higher prevalence of never receiving a Pap test prior to 21 (35.4% vs. 22.1%, p<0.001), but a lower ICC incidence at 21-23 (0.98 vs. 1.55 per 100,000, p<0.001).

conclusionWhile US females born in 1986-1991 were less likely to receive a Pap test before age 21, diagnoses of ICC in the early 20s were rare and lower than for those born in earlier years. This provides reassurance that the updated guidelines to delay screening until 21 has not resulted in a population-level increase in ICC rates among young women.

Indexed as

AdultDelayed DiagnosisFemaleHumansIncidencePapanicolaou TestSEER ProgramTime FactorsUnited StatesUterine Cervical NeoplasmsCervical cancerEpidemiologyPap testScreeningSEER

Identifiers

PMID27894752
PMCPMC5239725
OpenAlexW2554408242

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.